Shaping the future of animal health
Virbac group

A company dedicated
to animal health

Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical company exclusively dedicated to animal health. Ranked 8th worldwide and present in more than 100 countries, the company offers a comprehensive range of products and services intended for veterinarians, farmers and animal owners.

Corporate news

Nov 17 - Take your talent into new territories

Formalize an employer message to support the company's international growth. This is the objective of Virbac. Details from Laurence Garrido, Head of Corporate Human Resources.  

Oct 03 - StMichel-Virbac monohull to be built by Multiplast

Last April, Jean-Pierre Dick and his sponsors announced their return to monohull racing with the goal of taking part in the Ocean Masters events between 2015 and 2017, the highlight of which will be the Vendée Globe 2016. Designed by Verdier VPLP, StMichel-Virbac will be built at the Vannes Multiplast boatyard. The new boat will be launched next summer.  

Sep 05 - Virbac opens its new site for production of sterile injectable forms at Carros

Virbac is the world's eighth largest pharmaceutical company operating solely in the field of animal health. To ensure its continued growth in the ruminant market, Virbac opened the 4th September Virbac 8, its new production site in Carros (Alpes-Maritimes, France) which will manufacture sterile, mainly injectable, forms for ruminants.

Join Virbac

Career opportunities, company values, testimonials... Discover our career section.

Customer driven innovation

To meet the customers' essential needs, in almost all the therapeutic segments and for nearly all species. Such is the philosophy of Virbac innovation. For this purpose, the company develops...

Financial public releases

Oct 27 - Virbac agrees to acquire veterinary assets from Eli Lilly in the United States

Virbac announces that it has entered into an agreement with Eli Lilly and Company to acquire major United States veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.

Oct 16 - 2014 third quarter consolidated sales

Confirmation of the rebound of growth in the third quarter

Aug 29 - 2014 half year results

Half-year results impacted by foreign exchange and the low level of activity in the United States

Corporate responsibility

Company culture, economic and social responsibility, citizenship, environment... From its very beginning, forty years ago, Virbac has taken a long-term view.